Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study (vol 18, pg 1435, 2018)

被引：0
|
作者：
Jeng, L-B
机构：
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2022年 / 22卷 / 10期
关键词：
D O I：
10.1111/ajt.16948
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：2489 / 2490
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED TACROLIMUS AND EARLY STEROID ELIMINATION REGIMEN IN DE NOVO PEDIATRIC RENAL TRANSPLANT RECIPIENTS: 12-MONTH DATA FROM THE CRADLE STUDY.
    Toenshoff, B.
    Ettenger, R.
    Christian, M.
    Bjerre, A.
    Strologo, L. D.
    Marks, S. D.
    Pape, L.
    Martzloff, E-D.
    Rauer, B.
    Ng, J.
    Lopez, P. M.
    PEDIATRIC TRANSPLANTATION, 2017, 21 : 1 - 1
  • [32] Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study
    Lehner, Frank
    Budde, Klemens
    Zeier, Martin
    Wuethrich, Rudolf P.
    Reinke, Petra
    Eisenberger, Ute
    Muehlfeld, Anja
    Arns, Wolfgang
    Stahl, Rolf
    Heller, Katharina
    Witzke, Oliver
    Wolters, Heiner H.
    Suwelack, Barbara
    Klehr, Hans Ulrich
    Stangl, Manfred
    Hauser, Ingeborg A.
    Nadalin, Silvio
    Porstner, Martina
    May, Christoph
    Paulus, Eva-Maria
    Sommerer, Claudia
    TRANSPLANT INTERNATIONAL, 2014, 27 (11) : 1192 - 1204
  • [33] Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study.
    Mulgaonkar, S.
    Qazi, Y.
    Kim, D.
    Peddi, V.
    McCague, K.
    Patel, D.
    Wiseman, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 259 - 259
  • [34] EVEROLIMUS WITH REDUCED TACROLIMUS PROVIDES COMPARABLE EFFICACY VS. STANDARD TACROLIMUS FOLLOWING LIVING DONOR LIVER TRANSPLANTATION: A 12-MONTH SUBGROUP ANALYSIS FROM THE PIVOTAL H2307 STUDY
    Jeng, Long-Bin
    Lee, Sung-Gyu
    Soin, Arvinder Singh
    Lee, Wei-Chen
    Tokat, Yaman
    Lim, Kieron B.
    El Meteini, Mahmoud
    Lopez, Patricia
    Kochuparampil, Jossy
    Sips, Carole
    Kaneko, Shuhei
    Yagi, Takahito
    TRANSPLANT INTERNATIONAL, 2017, 30 : 65 - 65
  • [35] Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results
    Levy, Gary
    Schmidli, Heinz
    Punch, Jeffrey
    Tuttle-Newhall, Elizabeth
    Mayer, David
    Neuhaus, Peter
    Samuel, Didier
    Nashan, Bjorn
    Klempnauer, Juergen
    Langnas, Alan
    Calmus, Yvon
    Rogiers, Xavier
    Abecassis, Michael
    Freeman, Richard
    Sloof, Maarten
    Roberts, John
    Fischer, Lutz
    LIVER TRANSPLANTATION, 2006, 12 (11) : 1640 - +
  • [36] Efficacy and Safety of Everolimus with Early Reduction or Elimination of Tacrolimus in 719 de Novo Liver Transplant Recipients - Results at 12 Months
    De Simone, P.
    Nevens, F.
    Duvoux, C.
    Koneru, B.
    McCormack, L.
    McCaughan, G.
    Navasa, M.
    Dong, G.
    Hexham, J. M.
    Junge, G.
    Fung, J.
    TRANSPLANTATION, 2012, 94 (10) : 220 - 220
  • [37] Everolimus with Early Reduction or Elimination of Tacrolimus in 719 De Novo Liver Transplant Recipients-12 Month Efficacy and Safety Results from H2304 Study
    Fung, J.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fischer, L.
    Duvoux, C.
    Chavin, K. D.
    Koneru, B.
    Jiang, H.
    Hexham, J. M.
    Junge, G.
    De Simone, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 28 - 28
  • [38] Efficacy and Safety of Early Use of Everolimus in Standard and Extended Criteria Deceased Donor KidneyTransplant Recipients: 12-Month Preliminary Results of a Randomized Single Center Trial
    Fernandes-Charpiot, I.
    Caldas, H.
    Mazeti, C.
    Baptista, M.
    Razera, J.
    Abbud-Filho, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 597 - 598
  • [39] SAFETY AND EFFICACY OF EARLY USE OF EVEROLIMUS IN COMBINATION WITH REDUCED TACROLIMUS VS STANDARD TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: HEPHAISTOS STUDY 12 MONTHS DATA
    Schlitt, H. J.
    Nashan, B.
    Schemmer, P.
    Pascher, A.
    Klein, C. G.
    Neumann, U.
    Kroeger, I.
    Wimmer, P.
    Braun, F.
    TRANSPLANT INTERNATIONAL, 2019, 32 : 25 - 25
  • [40] Effect of Everolimus with Reduced Tacrolimus on Renal Function after Living-Donor Liver Transplantation (LDLT): 1-Year Results from a Randomized International Study
    Lee, Gyu S.
    Jeng, L. -B.
    Soin, A. S.
    Suh, K. -S.
    Joo, Jin D.
    Lee, W. C.
    Inomata, Y.
    Lopez, P.
    Kochuparampil, J.
    Sips, C.
    Kaneko, S.
    Levy, G.
    TRANSPLANTATION, 2017, 101 (05) : 364 - 365
12345